A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes

Publisher： John Wiley & Sons Inc

E-ISSN： 1755-5922|34|5|330-336

ISSN： 1755-5914

Source： CARDIOVASCULAR THERAPEUTICS (ELECTRONIC), Vol.34, Iss.5, 2016-10, pp. : 330-336

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Characteristics, Treatment and Outcome of Patients with Non-ST-Elevation Acute Coronary Syndromes and Multivessel Coronary Artery Disease: Observations from PURSUIT (Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrelin Therapy)

By  

Cardiology, Vol. 98, Iss. 4, 2003-01 ,pp. : 195-201

Karger

Access to resources Recommend Favorite

The emerging role of platelet glycoprotein IIb/IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes

By Bolognese Leonardo  

Current Medical Research and Opinion, Vol. 23, Iss. 6, 2007-06 ,pp. : 1217-1226

Informa Healthcare

Access to resources Recommend Favorite

Patupilone (Epothilone B) for Recurrent Glioblastoma: Clinical Outcome and Translational Analysis of a Single-Institution Phase I/II Trial

By  

Oncology, Vol. 83, Iss. 1, 2012-06 ,pp. : 1-9

Karger

Access to resources Recommend Favorite

Current Knowledge of the Platelet Glycoprotein IIb/IIIa Receptor Antagonists for the Treatment of Coronary Artery Disease

By  

Pathophysiology of Haemostasis and Thrombosis, Vol. 30, Iss. 3, 2004-11 ,pp. : 27-43

Karger

Access to resources Recommend Favorite

Use of Glycoprotein IIb/IIIa Inhibitors in Patients with Acute Coronary Syndromes Undergoing Coronary Revascularization

By  

Pathophysiology of Haemostasis and Thrombosis, Vol. 29, Iss. 1, 2004-11 ,pp. : 69-71

Karger

Access to resources Recommend Favorite